New Treatment in Advanced Thyroid Cancer

Table 2

Summary of results of the most important clinical trials conducted in advanced thyroid carcinoma.

Drug	Target	Type of study (ref)	Histology	No. of patients	PR (%)	SD (%)
Sunitinib	VEGFR 1-2; PDGF, RET,	Phase II [37]	DTC	31	13%	68%
	c-KIT, FLT3	Phase II [39]	DTC (29),  MTC (6)	35	31%	46%
		Phase II [41]	DTC	30	23%	68%
		Phase II [42]	DTC	41	15%	56%
Sorafenib	VEGFR 1-2; PDGF, RET; RAF MAPK	Phase II [43]	MTC (15)/DTC (19)	34	15%	74%
		Phase II [44]	DTC	32	25%	34%
		Phase II [45]	MTC	15	6%	62%
		Phase II [47]	MTC	30	21%	53%
Vandetanib	VEGFR 1-2; EGFR, RET	Phase II [48]	MTC	19	16%	53%
		Phase III [49]	MTC	231	44%	20%
Motesanib	VEGFR 1-2-3; EGFR, RET	Phase II [50]	MTC	91	2%	48%
Axitinib	VEGF	Phase II [53]	MTC (11)/DTC (45)Other (4)	60	30%	38%
XL 184	VEGF, MET, RET, c-KIT, FLT3	Phase I [54]	MTC	37	29%	41%
Pazopanib	VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-c-Kit	Phase II [55]	DTC	37	49%
Lenvatinib	VEGFR1-3, FGFR1-4, RET, KIT PDGFRβ	Phase II [58]	DTC	58	50%